NEOVACS (ALNEV.PA)
FR001400TG47 - Common Stock
ALNEV gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 74 industry peers in the Biotechnology industry. ALNEV has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, ALNEV is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year ALNEV has reported negative net income.
ALNEV had a negative operating cash flow in the past year.
ALNEV had negative earnings in each of the past 5 years.
ALNEV had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of ALNEV (-80.72%) is worse than 80.30% of its industry peers.
The Return On Equity of ALNEV (-190.29%) is worse than 72.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -80.72% | ||
| ROE | -190.29% | ||
| ROIC | N/A |
ROA(3y)-15.81%
ROA(5y)-38.36%
ROE(3y)-17.31%
ROE(5y)-74.96%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ALNEV's Gross Margin of 42.42% is in line compared to the rest of the industry. ALNEV outperforms 57.58% of its industry peers.
The Profit Margin and Operating Margin are not available for ALNEV so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 42.42% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ALNEV does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALNEV has more shares outstanding
The number of shares outstanding for ALNEV has been increased compared to 5 years ago.
The debt/assets ratio for ALNEV has been reduced compared to a year ago.
2.2 Solvency
ALNEV has an Altman-Z score of -2.44. This is a bad value and indicates that ALNEV is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.44, ALNEV is doing worse than 60.61% of the companies in the same industry.
ALNEV has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.03, ALNEV is doing good in the industry, outperforming 72.73% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.44 |
ROIC/WACCN/A
WACC5.12%
2.3 Liquidity
A Current Ratio of 0.66 indicates that ALNEV may have some problems paying its short term obligations.
ALNEV's Current ratio of 0.66 is on the low side compared to the rest of the industry. ALNEV is outperformed by 84.85% of its industry peers.
A Quick Ratio of 0.66 indicates that ALNEV may have some problems paying its short term obligations.
ALNEV's Quick ratio of 0.66 is on the low side compared to the rest of the industry. ALNEV is outperformed by 81.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.66 | ||
| Quick Ratio | 0.66 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 100.00% over the past year.
ALNEV shows a strong growth in Revenue. In the last year, the Revenue has grown by 558.39%.
The Revenue has been growing by 161.65% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.99%
Revenue 1Y (TTM)558.39%
Revenue growth 3Y161.65%
Revenue growth 5YN/A
Sales Q2Q%144.47%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ALNEV. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 0 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
ALNEV does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NEOVACS
EPA:ALNEV (1/14/2025, 7:00:00 PM)
0.93
-0.07 (-6.95%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap139.50K
Analysts86.67
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.2 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.01 | ||
| P/tB | 0.01 | ||
| EV/EBITDA | 0 |
EPS(TTM)-9.66
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-11.23
FCFYN/A
OCF(TTM)-9.77
OCFYN/A
SpS4.54
BVpS124.2
TBVpS124.2
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -80.72% | ||
| ROE | -190.29% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 42.42% | ||
| FCFM | N/A |
ROA(3y)-15.81%
ROA(5y)-38.36%
ROE(3y)-17.31%
ROE(5y)-74.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.02 | ||
| Cap/Depr | 0.69% | ||
| Cap/Sales | 32.13% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.66 | ||
| Quick Ratio | 0.66 | ||
| Altman-Z | -2.44 |
F-Score4
WACC5.12%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5265.5%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.99%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)558.39%
Revenue growth 3Y161.65%
Revenue growth 5YN/A
Sales Q2Q%144.47%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y32.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y85.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y86.46%
OCF growth 3YN/A
OCF growth 5YN/A